ROBINS CHAD M 4

4 · Adaptive Biotechnologies Corp · Filed Feb 21, 2025

Form 4

Period: 2025-02-19

DirectorCEO and Chairman

Transactions

Exercise/Conversion
Common Stock
2025-02-20$6.32/sh+99,107$626,356→ 2,675,808 total
Sale
Common Stock
2025-02-20$8.44/sh−99,107$836,463→ 2,576,701 total
Exercise/Conversion
Stock Option (right to buy)
2025-02-19−186,080→ 99,107 total
Exercise: $6.32Exp: 2025-06-09→ Common Stock (186,080 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-02-20−99,107→ 0 total
Exercise: $6.32Exp: 2025-06-09→ Common Stock (99,107 underlying)
Exercise/Conversion
Common Stock
2025-02-19$6.32/sh+186,080$1,176,026→ 2,762,781 total
Sale
Common Stock
2025-02-19$8.46/sh−186,080$1,574,237→ 2,576,701 total

Footnotes (4)

[F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option would have expired on June 9, 2025.
[F2]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.67, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
[F3]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.69, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
[F4]The option is fully vested and exercisable.

Documents

1 file